9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Estimated reading time: < 1 min

Condition: Carcinoma, Non-small-cell Lung

Estimated Enrollment: 59

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Adverse events (AEs) using CTCAE v4.03 (to determine dose limiting toxicities (DLTs) and maximum tolerated dose (MTD)),  Objective response rate (ORR), using best objective response by irRECIST,  Duration of response (DoR), Progression free survival (PFS)

Interventions: Defactinib, Pembrolizumab

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: May 2019

Completion Date: December 2021

Last  Posted Date: March 19, 2018

Location: Belfast Health and Social Care Trust, Cancer Centre, Lisburn Road, Belfast, United Kingdom

Website Link: https://ClinicalTrials.gov/show/NCT02758587

Was this article helpful?
Dislike 0